论文部分内容阅读
目的探讨左卡尼汀联合促红细胞生成素治疗慢性心力衰竭(CHF)合并贫血的临床疗效。方法选取2013年3月—2014年1月广西柳州钢铁集团公司医院收治的CHF合并贫血患者60例,随机分为试验组和对照组,各30例。对照组患者给予常规综合治疗,试验组患者在常规综合治疗基础上给予左卡尼汀联合促红细胞生成素治疗,均治疗4个月。比较两组患者治疗前后血红蛋白(Hb)、游离脂肪酸(FFA)、红细胞膜K+-Na+-ATP酶活性及左心室射血分数(LVEF)。结果两组患者治疗前Hb、FFA、红细胞膜K+-Na+-ATP酶活性及LVEF比较,差异无统计学意义(P>0.05);试验组患者治疗后Hb、红细胞膜K+-Na+-ATP酶活性及LVEF高于对照组,FFA低于对照组,差异有统计学意义(P<0.05)。结论左卡尼汀联合促红细胞生成素治疗CHF合并贫血具有一定疗效,能有效改善患者贫血及心功能。
Objective To investigate the clinical efficacy of levocarnitine combined with erythropoietin in the treatment of chronic heart failure (CHF) and anemia. Methods Sixty CHF patients with CHF were enrolled in the hospital from March 2013 to January 2014 in Guangxi Liuzhou Iron and Steel Group Hospital and randomly divided into experimental group and control group with 30 cases in each group. Patients in the control group were given conventional comprehensive treatment. Patients in the test group were treated with levocarnitine and erythropoietin on the basis of conventional comprehensive treatment for 4 months. The levels of hemoglobin (Hb), free fatty acid (FFA), erythrocyte membrane K + -Na + -ATPase activity and left ventricular ejection fraction (LVEF) were compared between the two groups before and after treatment. Results There was no significant difference in Hb, FFA, K + -Na + -ATPase activity and LVEF between the two groups before treatment (P> 0.05). The activity of Hb, erythrocyte membrane K + -Na + -ATPase And LVEF higher than the control group, FFA lower than the control group, the difference was statistically significant (P <0.05). Conclusion L-carnitine combined with erythropoietin in CHF patients with anemia has a certain effect, can effectively improve patients with anemia and cardiac function.